MedTrace Logo

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

NCT02632448 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2025-05-02

No results posted yet for this study

Summary

The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.

Conditions

Interventions

DRUG

LY2880070

Capsules

DRUG

Gemcitabine

50 to 600 milligrams per square meter of body surface area (mg/m2)

Sponsors & Collaborators

  • Esperas Pharma Inc.

    lead OTHER

Principal Investigators

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-16
Primary Completion
2025-04-14
Completion
2025-04-14
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Croatia
  • Poland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02632448 on ClinicalTrials.gov